Cargando…

Patient preference for needleless factor VIII reconstitution device: the Italian experience

BACKGROUND: Needlestick injuries, mostly due to unsafe needle devices, are a frequent adverse event among health care workers and patients on chronic treatment, such as hemophiliacs. To improve the safety of these procedures, a needleless reconstitution system, Bio-Set(®) has been implemented for th...

Descripción completa

Detalles Bibliográficos
Autores principales: Musso, Roberto, Santoro, Rita, Coppola, Antonio, Marcucci, Maura, Sottilotta, Gianluca, Targhetta, Roberto, Zanon, Ezio, Franchini, Massimo
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2915532/
https://www.ncbi.nlm.nih.gov/pubmed/20689694
_version_ 1782184934445678592
author Musso, Roberto
Santoro, Rita
Coppola, Antonio
Marcucci, Maura
Sottilotta, Gianluca
Targhetta, Roberto
Zanon, Ezio
Franchini, Massimo
author_facet Musso, Roberto
Santoro, Rita
Coppola, Antonio
Marcucci, Maura
Sottilotta, Gianluca
Targhetta, Roberto
Zanon, Ezio
Franchini, Massimo
author_sort Musso, Roberto
collection PubMed
description BACKGROUND: Needlestick injuries, mostly due to unsafe needle devices, are a frequent adverse event among health care workers and patients on chronic treatment, such as hemophiliacs. To improve the safety of these procedures, a needleless reconstitution system, Bio-Set(®) has been implemented for the sucrose-formulated recombinant factor VIII (rFVIII-FS) Kogenate(®) Bayer (Bayer Healthcare, Berlin, Germany). The aim of this study was to collect patients’ satisfaction and safety data regarding the administration of rFVIII-FS with this new device. METHODS: This was a multicenter, prospective, postmarketing surveillance study collecting data from seven Italian Haemophilia Centers within the framework of an international project involving patients from nine European countries. The patients were asked to fill out two preference questionnaires (one assessing the old method and one assessing the new method) directly after the training and two further preference questionnaries (assessing the new method) after a period of about 3 and 12 months. RESULTS: A total of 44 male hemophilia A patients were included in the analysis. At the end of the 12-month observation period, physicians assessed the patients’ satisfaction with Kogenate(®) Bayer with Bio-Set(®) in 40.9% (n = 18) as “very satisfied” and in 45.5% (n = 20) as “satisfied”, whereas “not satisfied” ratings were given for 9.1% (n = 4) of patients (data missing from two patients, 4.5%). The compliance of the patients compared with the last method before switch to the Bio-Set(®) device was rated as “better”, “equal”, and “worse” in 72.7% (n = 32), 20.5% (n = 9), and 2.3% (n = 1) of patients, respectively. Three patients (6.8%) experienced adverse events, but only one event was related to rFVIII infusion (inhibitor development in a patient who had little prior exposure to rFVIII) itself and not to the new device per se. CONCLUSIONS: The great majority of Italian patients who switched from an older method of rFVIII reconstitution to rFVIII-FS with the new reconstitution method preferred the new method. The ease of use, perceived safety from needlesticks, and the speed of reconstitution were identified as main advantages by the majority of patients.
format Text
id pubmed-2915532
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-29155322010-08-05 Patient preference for needleless factor VIII reconstitution device: the Italian experience Musso, Roberto Santoro, Rita Coppola, Antonio Marcucci, Maura Sottilotta, Gianluca Targhetta, Roberto Zanon, Ezio Franchini, Massimo Int J Gen Med Original Research BACKGROUND: Needlestick injuries, mostly due to unsafe needle devices, are a frequent adverse event among health care workers and patients on chronic treatment, such as hemophiliacs. To improve the safety of these procedures, a needleless reconstitution system, Bio-Set(®) has been implemented for the sucrose-formulated recombinant factor VIII (rFVIII-FS) Kogenate(®) Bayer (Bayer Healthcare, Berlin, Germany). The aim of this study was to collect patients’ satisfaction and safety data regarding the administration of rFVIII-FS with this new device. METHODS: This was a multicenter, prospective, postmarketing surveillance study collecting data from seven Italian Haemophilia Centers within the framework of an international project involving patients from nine European countries. The patients were asked to fill out two preference questionnaires (one assessing the old method and one assessing the new method) directly after the training and two further preference questionnaries (assessing the new method) after a period of about 3 and 12 months. RESULTS: A total of 44 male hemophilia A patients were included in the analysis. At the end of the 12-month observation period, physicians assessed the patients’ satisfaction with Kogenate(®) Bayer with Bio-Set(®) in 40.9% (n = 18) as “very satisfied” and in 45.5% (n = 20) as “satisfied”, whereas “not satisfied” ratings were given for 9.1% (n = 4) of patients (data missing from two patients, 4.5%). The compliance of the patients compared with the last method before switch to the Bio-Set(®) device was rated as “better”, “equal”, and “worse” in 72.7% (n = 32), 20.5% (n = 9), and 2.3% (n = 1) of patients, respectively. Three patients (6.8%) experienced adverse events, but only one event was related to rFVIII infusion (inhibitor development in a patient who had little prior exposure to rFVIII) itself and not to the new device per se. CONCLUSIONS: The great majority of Italian patients who switched from an older method of rFVIII reconstitution to rFVIII-FS with the new reconstitution method preferred the new method. The ease of use, perceived safety from needlesticks, and the speed of reconstitution were identified as main advantages by the majority of patients. Dove Medical Press 2010-07-21 /pmc/articles/PMC2915532/ /pubmed/20689694 Text en © 2010 Musso et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Musso, Roberto
Santoro, Rita
Coppola, Antonio
Marcucci, Maura
Sottilotta, Gianluca
Targhetta, Roberto
Zanon, Ezio
Franchini, Massimo
Patient preference for needleless factor VIII reconstitution device: the Italian experience
title Patient preference for needleless factor VIII reconstitution device: the Italian experience
title_full Patient preference for needleless factor VIII reconstitution device: the Italian experience
title_fullStr Patient preference for needleless factor VIII reconstitution device: the Italian experience
title_full_unstemmed Patient preference for needleless factor VIII reconstitution device: the Italian experience
title_short Patient preference for needleless factor VIII reconstitution device: the Italian experience
title_sort patient preference for needleless factor viii reconstitution device: the italian experience
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2915532/
https://www.ncbi.nlm.nih.gov/pubmed/20689694
work_keys_str_mv AT mussoroberto patientpreferenceforneedlelessfactorviiireconstitutiondevicetheitalianexperience
AT santororita patientpreferenceforneedlelessfactorviiireconstitutiondevicetheitalianexperience
AT coppolaantonio patientpreferenceforneedlelessfactorviiireconstitutiondevicetheitalianexperience
AT marcuccimaura patientpreferenceforneedlelessfactorviiireconstitutiondevicetheitalianexperience
AT sottilottagianluca patientpreferenceforneedlelessfactorviiireconstitutiondevicetheitalianexperience
AT targhettaroberto patientpreferenceforneedlelessfactorviiireconstitutiondevicetheitalianexperience
AT zanonezio patientpreferenceforneedlelessfactorviiireconstitutiondevicetheitalianexperience
AT franchinimassimo patientpreferenceforneedlelessfactorviiireconstitutiondevicetheitalianexperience